Common cutaneous drug reactions

References

Key articles

Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ. 2003 Nov 22;327(7425):1222-5. Abstract

Gell PG, Coombs RRA, eds. Clinical aspects of immunology. 1st ed. Oxford: Blackwell; 1963.

Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986 Dec 26;256(24):3358-63. Abstract

Kuokkanen K. Drug eruptions: a series of 464 cases in the Department of Dermatology, University of Turku, Finland, during 1966-1970. Acta Allergol. 1972 Dec;27(5):407-38. Abstract

Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28(10):851-70. Abstract

Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239-45. Abstract

Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965 Jan;58(1):295-300.Full text  Abstract

Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med. 2009 May;102(5):186-94. Abstract

National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. September 2014 [internet publication].Full text

Reference articles

1. Aronson JK. Adverse drug reactions: history, terminology, classification, causality, frequency, preventability. In: Talbot J, Aronson JK, eds. Stephens’ detection and evaluation of adverse drug reactions: principles and practice. 6th ed. Oxford: Wiley-Blackwell; 2011.

2. Health Canada. Adverse reaction information. October 2012 [internet publication].Full text

3. Warrington R, Silviu-Dan F. Drug allergy. Allergy Asthma Clin Immunol. 2011 Nov 10;7(suppl 1):S10.Full text  Abstract

4. Gruchalla RS. Drug allergy. J Allergy Clin Immunol. 2003 Feb;111(suppl 2):S548-59. Abstract

5. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004 May 18;140(10):795-801. Abstract

6. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1977:10.

7. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ. 2003 Nov 22;327(7425):1222-5. Abstract

8. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7;358(6):568-79.Full text  Abstract

9. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003 Nov 1;68(9):1781-91.Full text

10. Gell PG, Coombs RRA, eds. Clinical aspects of immunology. 1st ed. Oxford: Blackwell; 1963.

11. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004 May;113(5):832-6. Abstract

12. Gonzalo-Garijo MA, de Argila D. Erythroderma due to aztreonam and clindamycin. J Investig Allergol Clin Immunol. 2006;16(3):210-1.Full text  Abstract

13. Akcam M, Artan R, Akcam FZ, et al. Nail discoloration induced by doxycycline. Pediatr Infect Dis J. 2005 Sep;24(9):845-6. Abstract

14. Rogers KC, Wolfe DA. Amiodarone-induced blue-gray syndrome. Ann Pharmacother. 2000 Sep;34(9):1075. Abstract

15. Jia Y, Lacouture ME, Su X, et al. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol. 2009 Nov-Dec;7(6):211-7. Abstract

16. Drucker AM, Wu S, Busam KJ, et al. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. Eur J Haematol. 2013 Feb;90(2):142-150. Abstract

17. Rosen AC, Wu S, Damse A, et al. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. 2012 Apr;97(4):1125-33.Full text  Abstract

18. Fischer A, Wu S, Ho AL, et al. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2013 Jun;31(3):787-97. Abstract

19. Chu D, Lacouture ME, Weiner E, et al. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer. 2009 Jan;7(1):11-9. Abstract

20. Minkis K, Garden BC, Wu S, et al. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013 Sep;69(3):e121-8. Abstract

21. Drucker AM, Wu S, Dang CT, et al. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat. 2012 Sep;135(2):347-54. Abstract

22. Fiorino G, Allez M, Malesci A, et al. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009 May 1;29(9):921-7.Full text  Abstract

23. Su X, Lacouture ME, Jia Y, et al. Risk of high-grade skin rash in cancer patients treated with cetuximab: an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology. 2009;77(2):124-33. Abstract

24. Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986 Dec 26;256(24):3358-63. Abstract

25. Kuokkanen K. Drug eruptions: a series of 464 cases in the Department of Dermatology, University of Turku, Finland, during 1966-1970. Acta Allergol. 1972 Dec;27(5):407-38. Abstract

26. Hernández-Salazar A, Rosales SP, Rangel-Frausto S, et al. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res. 2006 Oct;37(7):899-902. Abstract

27. Castro-Pastrana LI, Ghannadan R, Rieder MJ, et al. Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). J Popul Ther Clin Pharmacol. 2011;18:e106-e120. Abstract

28. Lecluse LL, Dowlatshahi EA, Limpens CE, et al. Etanercept: an overview of dermatologic adverse events. Arch Dermatol. 2011 Jan;147(1):79-94. Abstract

29. Goh CL. Nonoccupational contact dermatitis. Clin Dermatol. 1998 Jan-Feb;16(1):119-27. Abstract

30. Yip VL, Marson AG, Jorgensen AL, et al. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther. 2012 Dec;92(6):757-65. Abstract

31. Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples. Dermatologica. 1989;179(1):10-3. Abstract

32. Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother. 2008 Mar;42(3):387-96. Abstract

33. Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics. 2008 Feb;9(2):207-14. Abstract

34. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143-57.Full text  Abstract

35. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007 Mar;156(3):609-11. Abstract

36. Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol. 2009 Aug;9(8):322-8. Abstract

37. Ozkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges. 2008 Mar;6(3):181-8. Abstract

38. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011 Jul;124(7):588-97. Abstract

39. Lee A, Thomson J. Drug-induced skin reactions. In: Lee A, ed. Adverse drug reactions. 2nd ed. London: Pharmaceutical Press; 2006:125-56.

40. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28(10):851-70. Abstract

41. Wang L, Cheng L, Yuan Q, et al. Adverse drug reactions of Shuanghuanglian injection: a systematic review of public literatures. J Evid Based Med. 2010 Feb;3(1):18-26. Abstract

42. Polak ME, Belgi G, McGuire C, et al. In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. Br J Dermatol. 2013 Mar;168(3):539-49. Abstract

43. Haw WY, Polak ME, McGuire C, et al. In vitro rapid diagnostic tests for severe drug hypersensitivity reactions in children. Ann Allergy Asthma Immunol. 2016 Jul;117(1):61-6. Abstract

44. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239-45. Abstract

45. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965 Jan;58(1):295-300.Full text  Abstract

46. Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med. 2009 May;102(5):186-94. Abstract

47. National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. September 2014 [internet publication].Full text

48. Lee AY. Fixed drug eruptions: incidence, recognition, and avoidance. Am J Clin Dermatol. 2000 Sep-Oct;1(5):277-85. Abstract

49. Resuscitation Council (UK). Emergency treatment of anaphylactic reactions: guidelines for healthcare providers. July 2012 [internet publication].Full text

50. Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020 Apr;145(4):1082-123.Full text  Abstract

51. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000 Aug;115(2):149-53.Full text  Abstract

52. Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016 Jun;174(6):1194-227.Full text  Abstract

53. Mydlarski PR, Ho V, Shear NH. Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. J Cutan Med Surg. 2006 Sep-Oct;10(6):205-21. Abstract

54. Enk A, Hadaschik E, Eming R, et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Dtsch Dermatol Ges. 2017 Feb;15(2):228-41.Full text  Abstract

55. Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007 Jun;119(6):1497-503. Abstract

Use of this content is subject to our disclaimer